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Abstract 
Introduction:  Diabetes affects more than 425 million people worldwide with a lifetime risk of diabetic 
foot ulcer (DFU) of up to 25%. Management includes wound debridement, wound dressings, off-
loading, treatment of infection and ischaemia, optimising glycaemic control; use of advanced adjuvant 
therapies is limited by high cost and lack of robust evidence.
Methods and Analysis: A multicentre, seamless Phase II/III, open, parallel group, multi-arm multi-
stage randomised controlled trial in patients with a hard-to-heal DFU, with blinded outcome 
assessment. A maximum of 447 participants will be randomised (245 participants in Phase II and 202 
participants in Phase III).
The Phase II primary objective will determine the efficacy of treatment strategies including 
hydrosurgical debridement +/- decellularised dermal allograft, or the combination with negative 
pressure wound therapy, as an adjunct to treatment as usual (TAU), compared to TAU alone, with 
patients randomised in a 1:1:1:2 allocation. The outcome is achieving at least 50% reduction in index 
ulcer area at 4 weeks post randomisation.  
The Phase III primary objective will determine whether one treatment strategy, continued from Phase 
II, reduces time to healing of the index ulcer compared with TAU alone, with participants randomised 
in a 1:1 allocation. Secondary objectives will compare healing status of the index ulcer, infection rate, 
re-ulceration, quality of life, cost-effectiveness and incidence of adverse events over 52 weeks post 
randomisation.  
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Phase II and III primary endpoint analysis will be conducted using a mixed-effects logistic regression 
model and Cox Proportional Hazards regression respectively.  
A within-trial economic evaluation will be undertaken; the primary economic analysis will be a cost-
utility analysis presenting ICERs for each treatment strategy in rank order of effectiveness, with 
effects expressed as QALYs. 
The trial has pre-defined progression criteria for the selection of one treatment strategy into Phase III 
based on efficacy, safety and costs at 4 weeks.
Ethics and Dissemination: Ethics approval has been granted by NRES Committee Yorkshire & The 
Humber - Bradford Leeds Research Ethics Committee; approved 26th April 2017; (REC reference: 
17/YH/0055). There is planned publication of a monograph in NIHR journals and main trial results and 
associated papers in high-impact peer reviewed journals. 
Trial registration: ISRCTN64926597; Registered on 06/06/2017. 
Article Summary
Strengths and Limitations of this study:
 The multi-arm multi-stage design will allow early evaluation of multiple treatment strategies in 
a Phase II/III design, stopping treatments which fail to demonstrate sufficient improvement, 
evaluating only those showing greatest efficacy in a Phase III trial;
 Comparison of multiple treatment strategies to a shared control group, thus requiring fewer 
participants compared to conventional trial designs;
 Clear pre-defined progression criteria for the selection of the treatment strategy into Phase III;
 Pragmatic in the identification of patients with hard to heal ulcers;
 The target sample size allows only one treatment strategy to be taken forward into Phase III.
Page 3 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
3
Introduction
Diabetes currently affects more than 425 million people worldwide (1), and this is expected to 
increase to  629 million by 2045 (2).  A total of 21-30% of patients with diabetes develop peripheral 
neuropathy or lose sensation in their feet  (3, 4) and extrapolation from incidence studies suggests 
that lifetime incidence of diabetic foot ulcer (DFU) may be as high as 25% (5). More than 50% of 
DFUs  become infected, requiring hospitalisation, and 20% of infections result in amputation (6), 
contributing approximately 80% of non-traumatic amputations performed in the developed world (7).
In the UK, diabetes affects 4.5 million people (8) with approximately 64,000 having a DFU at any one 
time (9). In 2014-15 NHS England spent an estimated £1 billion on DFU treatment (10). This does not 
take into account the costs imposed on the public sector and society as a whole through working days 
lost, reductions in tax revenue, increases in benefit payments and social care resources. Furthermore, 
DFUs have a major impact upon patient health related quality of life (HRQoL), including impaired 
physical function, mental wellbeing and social interaction (11) .
Management of DFUs comprises provision of NICE recommended best ‘treatment as usual’ (TAU) 
through multi-disciplinary team (MDT) DFU clinics (podiatrists, diabetologists, vascular surgeons etc.) 
and concomitant treatment strategies including: optimising glycaemic control, sharp non-surgical 
debridement, dressing application, off-loading, treatment of infection and ischaemia (12). There are a 
number of advanced/adjuvant therapies but their use is limited by high unit cost and an absence of 
robust evidence. 
Despite implementation of MDT care, a national audit of over 33,000 ulcers reports 48.3% remain 
unhealed at 12 weeks (13).  Of those patients with less than the median reduction in DFU area at 4 
weeks (<53% reduction), only 9% went onto heal at 12 weeks (14), whilst those in the top half for 
healing at 4 weeks (≥53% reduction) had a higher probability of healing of 58% at 12 weeks. Delayed 
healing increases the probability of adverse sequelae including infection and amputation(6).  Drivers 
of the cost of care change with the need for hospitalisation: in a recent study community nurse visits 
accounted for 65% of total costs for healed and unhealed wounds managed in the outpatient setting, 
whereas 65% of costs in patients having amputation were incurred in secondary care (15). Thus 
implementation of adjuvant therapies, which are often more costly, is more likely to be cost effective in 
those patients identified as “hard to heal” (failing to decrease by >50% at 4 weeks), whereas those 
DFUs reaching >50% healing at 4 weeks are likely to heal without the need for more expensive 
interventions. Those DFU’s reported as unhealed at 12 weeks in the 2019 UK National Diabetic Foot 
Audit (13) may have benefitted from such therapies.
Establishing efficacious adjuvant therapies for use in non-healing wounds is a priority to improve 
healing rates and HRQoL, and reduce the risk of morbidity and cost. There is a paucity of high quality 
trials assessing adjuvant wound therapies in DFUs and NICE guideline NG19 and others have 
highlighted the need for randomised controlled trials (RCTs) of negative pressure wound therapy 
(NPWT) and other adjuvant therapies (12, 16). Technological advances in three adjuvant therapies 
mean they are now available for routine clinic use. 
1) NPWT is available in a small portable pump which doesn’t restrict patient movement. 
2) Sufficient surgical debridement which changes a chronic wound biology to an acute wound 
can now be undertaken using hydrosurgical debridement (HD) under local anaesthetic in 
clinic, enhancing patient experience and reducing costs by avoiding additional hospital visits 
for day-case surgery. This also allows wound bed preparation to a “graft ready state” for 
advanced wound adjuncts, a state which cannot be achieved by less aggressive debridement 
with wound debridement pads such as Debrisoft®. HD has been shown to be as effective as 
operating theatre surgical debridement in wound healing outcomes (17). 
3) Decellularised dermal allograft (DCD) has been used in the USA for treatment of DFU, with 
improved healing compared to standard care (18, 19) but cost has been prohibitive in the UK. 
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A novel DCD, prepared from skin donated by voluntary UK deceased donors has recently 
been developed within the NHS, is approved by the Human Tissue Authority (HTA) and 
available for use in the UK. DCD is prepared and supplied by NHS Blood and Transplant (a 
Department of Health Special Health Authority). However, the application of DCD requires 
surgical debridement to a ‘graft ready wound bed’ and it is not known whether the surgical 
debridement alone leads to improved healing in this setting.
Performing multiple RCTs to assess each intervention individually would be time consuming and 
expensive. Moreover, these therapies are often used in combination. The MIDFUT trial utilises an 
efficient, informative and ethical, adaptive, multi-arm, multi-stage (MAMS) design (20). This involves 
early evaluation of combinations of the candidate interventions in a Phase II/III design, stopping 
recruitment to treatment strategies which fail to demonstrate sufficient improvements in DFU healing, 
using an intermediate endpoint at 4 weeks post randomisation, and evaluating only one treatment 
strategy showing greatest efficacy in a Phase III trial. 
The evidence for adjuvant therapies for DFU treatment was reviewed in NICE guideline NG19 (12), 
which concluded that the quality of trials was poor, due to binary and early endpoints and small 
sample sizes. It recommended that future trials are sufficiently powered, with outcomes including time 
to healing, incidence and extent of amputation (major or minor), ulcer recurrence, HRQOL, adverse 
events, hospital admissions and length of stay. These findings were supported by a review by the 
International Working Group on the Diabetic Foot  (21).
In summary, quality data on the outcome of adjuvant therapies for DFU is rare. A 30% increase in 
prevalence of disease is anticipated by 2035, which will add to the already substantial costs of 
treating DFUs, in a time of global fiscal uncertainty. With international guidance advocating the need 
for robust RCTs in this area (21), and technical advancements in three adjuvant therapy options (HD, 
DCD and NPWT), an RCT to compare treatment strategies is timely. 
Objectives
In Phase II, the aim is to identify the most promising of the three treatment strategies compared to 
treatment as usual (TAU) using short-term efficacy and in Phase III, to investigate the clinical and cost 
effectiveness of one treatment strategy from Phase II compared to TAU in the treatment of patients 
with hard to heal DFUs.
Phase II Primary Objective
To determine the efficacy of the treatment strategies,
1) TAU + HD alone 
2) TAU + HD + DCD 
3) TAU + HD + NWPT + DCD
compared to TAU alone using the short-term intermediate outcome of achieving at least 50% 
reduction in index ulcer area at 4 weeks post randomisation (Phase II primary endpoint). 
Phase III Primary Objective 
To determine whether one treatment strategy continued from Phase II, as an adjunct to TAU reduces 
time to healing of the index ulcer compared with TAU alone. 
The primary endpoint is time to healing of the index ulcer from randomisation to the date the index 
ulcer is confirmed as healed at the first confirmation visit conducted by the blinded assessor 
(providing the index ulcer is confirmed as healed at a second clinical assessment two weeks later).
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Phase III Secondary Objectives: 
To compare one treatment strategy as an adjunct to TAU, continued from Phase II, with TAU alone 
for: 
 healing status of the index ulcer at 12, 20 and 52 weeks 
 rate of ulcer infection in the foot of the index ulcer over 52 weeks post randomisation 
 incidence of re-ulceration following healing of index ulcer over 52 weeks post randomisation 
 quality of life using Diabetic Foot Ulcer Scale Short Form (DFS-SF) and EuroQol - five 
dimensions (EQ-5D-5L) over 52 weeks post randomisation 
 incidence of adverse events (including amputation, infection in any ulcer on the foot of the 
index ulcer and hospital admission) over 52 weeks post randomisation 
 cost effectiveness over 52 weeks 
Phase III Exploratory Objective:
To explore factors prognostic of ulcer healing
Methods 
The MIDFUT trial is a multi-centre, seamless Phase II/III, open, parallel group, multi-arm multi-stage 
(MAMS) randomised controlled trial (RCT) in patients with a hard to heal DFU, with blinded outcome 
assessment. 
The MAMS trial design will allow an early evaluation of three candidate treatment strategies in a 
Phase II/III design. Randomisation to treatment strategies that fail to demonstrate sufficient 
improvement in index ulcer healing at the end of Phase II will be stopped. Only one treatment strategy 
showing greatest early efficacy will undergo clinical and cost-effectiveness assessment in Phase III 
(see Figure 1 for a schematic of the design).
Three treatment strategies will be compared to TAU in Phase II. Treatment strategies for which the 
estimated proportion of responders is less than 10% higher than the proportion of responders on TAU 
(absolute difference) will be dropped at the end of Phase II (response defined as achieving at least 
50% reduction in wound area of the index ulcer). One treatment strategy and TAU will be evaluated in 
Phase III.  If more than one treatment strategy shows a sufficient response in Phase II, then the 
decision on which treatment strategy to evaluate in Phase III will consider information on the safety 
profile and costs of the treatment strategies up to 4 weeks post randomisation.
A maximum of 447 participants will be recruited, 245 participants in Phase II and at most 220 
participants in Phase III. Recruitment at centres will continue without interruption between Phase II 
and Phase III.
All participants from Phases II and III will be followed up at weeks 1, 2, 4, 8, 12, 20 and 52 post-
randomisation (including those where healing of the index ulcer has been confirmed), or week 54 
where healing of the index ulcer is first reported at week 52 (see Figure 2). 
The trial includes a 9-month internal pilot phase in Phase II to evaluate the feasibility of recruitment 
and therefore delivery of the trial.  
Moreover, a Study Within a Trial (SWaT) will be included to determine the extent of agreement in the 
assessment of healing between central blinded photography review and the clinical assessment of 
healing. 
An interim analysis will be conducted after 220 patients have reached 52 weeks post-randomisation to 
re-estimate the overall loss to follow-up rate and the final sample size. The review will be conducted in 
a blinded manner.
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Recruitment/Consent 
The trial will be conducted in secondary care and community clinics that provide a MDT-DFU service 
(which includes as a minimum a clinician trained in each trial intervention, podiatrist, diabetologist, 
vascular surgeon and orthotist).
Patients under the care of the MDT-DFU out-patient clinics, with a current DFU, surgical debridement 
wound or minor amputation wound, will be assessed for eligibility in accordance with the criteria in 
Table 1.
Table 1 Inclusion and Exclusion criteria
Inclusion criteria
1. Aged  18 years
2. Diagnosis of Diabetes Mellitus (according to WHO criteria (22))
3. Has a chronic DFU or surgical debridement wound or open minor amputation and in the opinion 
of the attending clinical team is not on a healing trajectory despite usual best care for a minimum 
of 4 weeks since initial presentation at the MDT DFU service*
4. The index DFU has an area ≥0.8cm2
5. Ankle brachial index for the leg of the index ulcer ≥0.7 or non-compressible (measurements 
available in the participants notes taken within 3 months of randomisation can be used if no 
change in intervention or vascular events have occurred)
6. Expected to comply with the treatment strategies and follow up schedule
7. Consent to foot and wound photography
8. Consent to participate (written/witnessed verbal informed consent)
*Defined as failure to achieve >50% reduction in index ulcer area over a minimum of 4 weeks using 
local wound measurement policies.
Exclusion criteria
1. Has any current clinically infected DFU on the foot of the index ulcer (as per IDSA guidelines (23)) 
2. HbA1c>110mmol/mol (measurements available in the participants notes taken within 3 months of 
randomisation can be used if no change in intervention or vascular events have occurred)
3. Estimated glomerular filtration rate (eGFR) < 20mL/min/1.73m2 (measurements taken within 3 
months of randomisation can be used if no change in intervention or vascular events have 
occurred)  
4. Index ulcer duration >2 years
5. Planned or previous treatment with corticosteroids to an equivalent dose of prednisolone >10mg 
per day or other immunosuppressive/immunomodulating therapy within 4 weeks prior to 
randomisation
6. Has evidence of connective tissue disorders as a cause of ulceration (e.g. vasculitis or rheumatoid 
arthritis) 
7. Has evidence of dermatological disorders as a cause of ulceration (e.g. pyoderma gangrenosum 
or epidermolysis bullosa)
8. Planned or previous growth factor treatment within 4 weeks prior to  randomisation
9. Planned or previous revascularisation or foot surgery affecting healing on the foot of the index 
ulcer within the 4 weeks prior to randomisation
10.Index ulcer base has bone or joint involvement
11.Previously received DCD for the index ulcer within 4 weeks prior to randomisation
12.Previously received NPWT for the index ulcer within 4 weeks prior to randomisation
13.Previously received hydrosurgical or surgical debridement for the index ulcer within 4 weeks prior 
to randomisation
14.Has previously been randomised to the MIDFUT study
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15.Unable to receive one or more of the randomised treatment strategies for any reason at the 
discretion of the attending clinical team (e.g. risk of excessive bleeding, serious falls risk, known 
allergies to NPWT dressings or dCELL dermis preparation components)
Potentially eligible patients will receive a verbal explanation of the study and a Patient Information 
Leaflet (PIL) by the attending clinical/research team.  Strategies to encourage recruitment include:
 posters and/or leaflets in clinic waiting areas and other appropriate locations,
 letter and PIL sent to patients with their out-patient appointment letter,
 study included on relevant websites and research databases that can be accessed by 
members of the public,
 ethically approved tweets on Twitter.
Following information provision, patients will have as long as they need to consider participation and 
to discuss the study with their family and other healthcare professionals before consent to participate 
in the study is requested.  
Assenting patients will be invited to provide informed consent and complete an eligibility assessment. 
Full informed consent will be obtained for all participants prior to the participant undergoing 
procedures that are specifically for the purposes of the study and are not part of TAU at the 
participating centre. 
Witnessed consent by a representative who is independent of the trial will be available where 
relevant. 
Patients who provide written/witnessed verbal informed consent, but subsequently lose capacity will 
be withdrawn from the trial. 
Non-randomised patients
Participating research sites will complete a log of all patients presenting with a DFU and considered 
for the trial, but not recruited. Anonymised information to be collected includes age, sex, ethnicity, 
reason not eligible or reason declined participation.
Randomisation
Following confirmation of eligibility, consent and completion of baseline assessments, participants will 
be randomised.  In Phase II, randomisation will be in a 1:1:1:2 allocation ratio to the three treatment 
strategies and TAU group respectively, as an approximation to Dunnett’s recommendation (24).  In 
Phase III, randomisation will be in a 1:1 allocation ratio to one treatment strategy and TAU.  
Randomisation in both phases will use a minimisation algorithm, incorporating a random element, via 
a central 24-hour automated telephone or internet randomisation system, based at the Leeds Clinical 
Trials Research Unit (CTRU).  The dynamic allocation method will ensure the groups are well 
balanced for:
 Centre
 Aetiology (neuropathic or neuro-ischaemic) 
 Index ulcer duration (<6 months, ≥ 6 months) 
 Anatomical site (forefoot, mid/hindfoot)
 Presentation (DFU, surgical debridement wound, open minor amputation)
In addition, at the time of randomisation, 25% of participants will be randomly selected to have 
photographs of the index ulcer taken, if it is unhealed, at weeks 12, 20 and 52, for central blinded 
review.
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Blinding
Due to the nature of the treatment strategies it is not possible to blind participants, the clinicians or 
research team to the treatment group allocation.  However, primary outcome assessments will be 
conducted by an independent clinical assessor with no knowledge of treatment allocation.  To mitigate 
risk of assessment bias the blinded assessor will also have no access to participant notes or trial 
Case Report Forms (CRFs). Blinding will be maintained when tracings and photographs at week 4, 
and confirmation of the index ulcer healing assessments, are returned to the CTRU (e.g. through 
separate mail or independent clerical staff).
For the Phase II primary outcome and Phase III exploratory objective, a blinded assessor at each site 
will complete an acetate tracing and take a 2D digital photograph of the index ulcer at week 4. 
Measurements will be obtained from the index ulcer tracing using ‘Image J’ software (25) by a 
member of the CTRU team who is independent of the research teams at recruiting sites and blind to 
treatment allocation. A photograph of the index ulcer will be taken as a back-up in the event that a 
tracing cannot be taken or is of insufficient quality to determine the index ulcer outline. 
For the Phase III primary endpoint, all participants recruited to both Phase II and III will also have a 
photograph taken of the reported healed index ulcer by the blinded assessor within 3 days of healing 
being reported and two weeks later as a confirmation of healing, which will undergo blinded central 
review.
 
Photographs taken of healed and of unhealed index ulcers for randomly selected participants will be 
submitted for central blinded photography review by clinical members of the Trial Management Group 
who will not be aware of the participant’s identity, treatment group or time point at which the 
photograph was taken. 
Interventions
All randomised treatment strategies will be applied to the index ulcer as a “once only intervention” on 
the day of randomisation in the MDT-DFU service clinic, with the exception of NPWT which will be 
applied until the 2-week visit.  Treatment of any other ulcers will continue as per the treating clinician 
decision.
At baseline, randomisation and each follow-up visit all participants will receive TAU.  At the 
randomisation treatment visit, the participant will be randomised to receive the treatment strategy 
specific to the arm of the trial for the index ulcer. This will include one or more of the following: 
Treatment as usual (TAU)
Participants will receive the minimum standard care provided by the recruiting centre. This will be in 
line with NICE guidelines (12) and is likely to include attendance at the MDT-DFU service clinic(s) at 
least fortnightly until healing is confirmed for wound assessment, sharp non-surgical debridement of 
callous/non-viable tissue, review of off-loading and to optimise diabetes and wound assessment as 
required, including community services visits, typically 1 to 2 times weekly.  In line with NICE 
guidelines, use of removable below-knee walking device or removable cast walker will be 
encouraged. Wound dressing changes will be performed between clinic visits according to local 
policies.
Hydrosurgical Debridement (HD)
Hydrosurgical Debridement (HD), a one-off procedure on the day of randomisation, applies saline at 
high pressure via a pump through a hand piece. This has an operating window located at the 
instrument’s distal tip. During operation the flow of pressurised saline creates a local vacuum. As the 
operating window of the handset is passed over the tissue, non-viable material and debris are 
removed.  The ulcer bed is debrided to healthy bleeding tissue which may require local anaesthetic.
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Negative Pressure Wound Therapy (NPWT)
Negative Pressure Wound Therapy (NPWT), applied on the day of randomisation, consists of a foam 
dressing cut to shape and applied to the wound. An air-tight seal is established with a film dressing; 
this is then connected to a pump which applies gentle suction to the wound. This allows the removal 
of fluid from the wound, which is collected in a canister attached to the pump, which is carried by the 
participant at all times in the bag provided. Alternatively, a self-contained system consisting of a 
disposable NPWT pump attached to an absorbent adhesive dressing may be used. The dressing is 
usually changed at least once a week, and the NPWT will be applied for 2 weeks post randomisation. 
Decellularised Dermal Allograft (DCD)
Decellularised Dermal Allografts are prepared from split skin grafts obtained from deceased human 
tissue donors, which are processed and sterilised. Processing retains the normal skin structure, but 
removes donor cells and cell remnants meaning the graft is not rejected and functions as a permanent 
tissue replacement. Upon receipt at participating sites, the graft will be stored between 0-40oC until the 
expiry date stated on the graft label. Prior to application the graft is soaked in a bowl of sterile saline 
solution for 15 minutes. The graft is then cut to size using sterile scissors and applied directly to the 
debrided wound bed, epidermal side upwards. Following application, the ulcer is covered with a non-
adherent contact layer and a secondary bolster dressing or NPWT (as per randomisation).  In those 
DFUs allocated to DCD, the wound bed is not debrided for 4 months post-treatment, unless clinically 
indicated, although debridement of wound edge and surrounding tissue can continue as per TAU. 
Assessments/data collection and follow-up
Baseline Assessment
Participant demographics including date of birth, gender, ethnicity, NHS number, and site of the index 
ulcer will be recorded.  
Clinical history will be recorded including smoking history, duration and type of diabetes, number of 
ulcers and index ulcer characteristics e.g. first or recurrent ulcer, aetiology, existing wound therapies 
and SINBAD classification (26).  Initial index ulcer area tracing (using acetate) will also be obtained.  
Participants will be asked to complete quality of life questionnaires: Diabetic Foot Scale –Short Form 
(DFS-SF) and the EuroQoL-5D 5 level (EQ-5D-5L).
Randomisation and application of the treatment strategy will take place after baseline assessments 
and questionnaires have been completed, on the same day.
Information collected post treatment will include details of the treatment strategy applied to the index 
ulcer and to any other ulcers on the foot of the index ulcer, and expected adverse events (AEs) and 
serious adverse events (SAEs).  Post HD debridement index ulcer area acetate tracing and 
photographs will be obtained.
Follow-up Assessments
At a routine clinic assessment at week 1 and at week 2, 4, 12, 20 and 52 post-randomisation the 
following assessments will be conducted by a member of the clinical research team (clinician, clinical 
research nurse or registered healthcare professional): healing status of the index ulcer, episodes of 
infection in the foot of the index ulcer (IDSA criteria), revascularisation of the index limb, index ulcer 
treatments and expected AEs or SAEs.  In addition, at weeks 1 and 2 post-randomisation, an 
assessment of compliance with NPWT and DCD (where applicable), and at weeks 2 to 52 post-
randomisation an assessment of re-ulceration of the index ulcer will be conducted. At week 2 and 
week 4 post randomisation, an acetate tracing and photograph of the index ulcer post sharp non-
surgical debridement (where clinically indicated) will be taken; at week 4 this is conducted by a 
blinded assessor (clinician, research nurse or registered healthcare professional).
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Patient questionnaires (DFS-SF, EQ-5D-5L and Health Resource Utilisation (HRU)) will be completed 
at weeks 4, 12, 20 and 52 post-randomisation; the HRU questionnaire will also be completed at week 
8 post-randomisation.
 
Healing and Re-ulceration Assessments
Healing is defined as complete closure of the ulcer: 100% re-epithelialisation of the wound surface 
with the absence of drainage, confirmed by blinded assessment of index ulcer healing status at two 
consecutive assessments two weeks apart (27).
Healing of the index ulcer will be reported in one of the following scenarios;
 By the Research Nurse/Registered Healthcare Professional at a research visit. 
 During the participant’s routine appointment at the MDT-DFU service clinic, podiatry clinic, GP 
practice nurse and/or at home by district nurses as per treatment as usual 
 Patient self-reporting to the research team or to the attending clinical team in between routine 
appointments who will then inform the research team.
The attending clinical team will contact the research team to report the date the index ulcer was first 
noted as healed, who will then arrange an initial visit within 3 days of healing of the index ulcer first 
being reported and a 2 week follow-up visit (+/- 3 days) with the blinded assessor to assess index 
ulcer healing status and conduct photography. 
Re-ulceration is defined as recurrence of a full thickness break in the epithelium at the same location 
as the index ulcer (28). Re-ulceration of the index ulcer will be established either by participant self-
referral to the research team, at a routine clinic or research appointment or by continuous screening 
of new referrals to the MDT-DFU service clinic where participants will be flagged to the research team 
by the attending clinical team. Re-ulceration of the index ulcer will be confirmed by a blinded 
assessor, within 7 days of re-ulceration being reported, with reference to the photograph of the foot 
taken at the randomisation visit, photography undertaken and the date of re-ulceration of the index 
ulcer recorded. 
Sample size
The planned maximum sample size is 447 patients, 245 patients in Phase II and 202 patients in 
Phase III.  The apportionment of participants to Phase II and Phase III was estimated using a series 
of simulation studies.
In Phase II, 49 patients per treatment strategy arm and 98 patients in the TAU arm will be recruited.  
The target effect size in Phase II is an absolute increase of 25% in the proportion of patients 
achieving at least a 50% reduction in wound area by 4 weeks post randomisation, assuming 39% 
reach at least a 50% reduction by week 4 in the TAU arm (local audit data) and 64% achieve this 
outcome in the treatment strategy arms.
An additional 101 patients will be recruited into each arm evaluated in Phase III, corresponding to a 
total (Phase II and III combined) of 150 in the remaining treatment strategy group and 199 in the TAU 
arm (total of 349 patients for evaluation in Phase III).
The minimum clinically important effect size in Phase III is a hazard ratio of 1.5, assuming a median 
time to healing of 21 weeks for the TAU arm (local audit data) and 14 weeks for the treatment strategy 
arms (18, 29-32) and 18.0% and 7.6% unhealed at 52 weeks in the TAU and treatment strategy 
group respectively (assuming exponential distribution for time to healing).
 
Several scenarios for the power of the trial have been considered. In all cases a 10% loss to follow-up 
by 4 weeks and 25% loss to follow up by 52 weeks is assumed. In the case where there is a single 
effective treatment strategy arm, the design has 83% power to recommend a truly effective treatment 
strategy (i.e. for it to progress from Phase II and for a significant result found at Phase III).  A 
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treatment strategy group that progresses to Phase III and which is significantly better than TAU at the 
2-sided 4% significance level (to control the family wise error rate at 5%) on the time to healing 
endpoint will be declared clinically effective. 
A formal sample size review will be conducted at 52 weeks, after 220 patients have been recruited, to 
re-estimate the proportion of patients lost to follow-up by 52 weeks post randomisation and the final 
sample size.  The review will allow the overall loss to follow-up to be estimated to a minimum 
precision ±5.7% (corresponding to half width of the 95%CI), assuming a maximum loss to follow-up of 
25%.
Progression criteria for Phase III
The minimum criterion for taking treatment strategies forward into Phase III will be defined as at least 
a 10% increase in the probability of achieving ≥50% reduction in index ulcer area at 4 weeks post 
randomisation above that observed for TAU, corresponding to the minimum clinically important 
difference (clinical opinion). If more than one treatment strategy passes this threshold at Phase II then 
the selection criteria will be based on a combination of efficacy, safety profile and cost of treatment 
strategies up to 4 weeks post-randomisation.  The progression criteria are provided in further detail in 
Table 2. 
Table 2 Phase II to Phase II Progression Criteria
The progression criteria for the selection of treatment strategies into Phase III is based on the 
following process:
1) Calculate the point estimate for the proportion of patients with ≥50% ulcer area reduction at 
4 weeks post randomisation in all 4 arms (Phase II endpoint). Drop treatment strategy arms 
for which this proportion is less than 10% higher (on the absolute scale) than that of TAU. 
That is, if the proportion for TAU is 39% then recommend dropping treatment strategies for 
which the proportion is less than 49%. Rank the remaining treatment strategies in order of 
clinical efficacy.
Note: An absolute improvement of 10% in the proportion of patients with ≥50% ulcer area reduction at 4 weeks 
post randomisation corresponds to the critical cut-point for the selection of treatment strategies based on 
clinical activity.
2) If more than one treatment strategy has a success rate at 4 weeks of at least 10% greater 
than TAU then summarise SAEs and rank order of treatment strategies in terms of their 
safety profile.  Only AEs and SAEs that are classified as expected and related to DFUs or 
trial treatment strategies, or ‘related and unexpected SAEs’ (RUSAEs) will be considered.  
Decision on whether to drop treatment strategies with the “least favourable” safety profile 
will be made by the Data Monitoring and Ethics Committee (DMEC).
 
3) If more than one treatment strategy remains after stages 1) and 2) then summarise 
treatment-related costs up to 4 weeks and rank order of treatment strategies by ascending 
cost of treatment versus TAU.  Decision on whether to drop the treatment strategies with 
the highest cost will be made by the DMEC. 
4) If no treatment strategies remain, recommend terminating the trial. If one remains, take this 
forward to Phase III. If more than one treatment strategy satisfies 1) to 3), take forward the 
top performing arm defined by clinical efficacy (the extent of improvement in the proportion 
of patients achieving the Phase II endpoint).
The trial will also have a futility rule to allow for stopping of the trial on the basis of no treatment 
strategy demonstrating at least 10% absolute improvement in the success rate of the Phase II primary 
outcome. This will be non-binding to allow the DMEC to make the final recommendations to the TSC 
on whether or not to stop the trial.
Statistical analysis
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Statistical analysis plans for Phase II and Phase III final analyses will be finalised and signed off 
before any data analyses are conducted.
The complete case population will be used for the analysis of the Phase II endpoint under the 
assumption that data are missing at random (MAR) (33). A sensitivity analysis will be considered if 
there is differential missing endpoint data observed across treatment arms.
Phase III analyses will use Intention to Treat (ITT) whereby patients will be analysed according to 
randomised treatment group.  A per-protocol population will also be defined.
For Phase III endpoint analyses, data from all participants recruited in Phase II and Phase III will be 
included.
Phase II Primary Endpoint Analysis
Primary analysis
Treatment effects and 95% CI on response at 4 weeks will be estimated from multivariable mixed-
effects logistic regression, including the minimisation factors and treatment group as fixed effects and 
centres as random effects. Simple contrasts for each treatment strategy compared to the TAU arm will 
be used.
Phase II secondary endpoint analysis
AEs and SAEs that are classified as expected and related to DFUs and trial treatment strategies, or 
‘related and unexpected SAEs’ (RUSAEs) will be summarised by treatment group. 
Mean per-patient costs of treatment, health car  use and total resource use, together with a measure 
of variance will be reported by treatment group.
Phase III Primary Endpoint Analysis
Primary analysis
The hazard ratios for the Phase III endpoint will be estimated using Cox Proportional Hazards 
regression with covariates for the minimisation factors, treatment arm (fixed effects) and centre 
(random effects) and stratification for the phase in which the patient was recruited. 
Phase III secondary endpoint analysis
Similar regression-based analyses will be used for other secondary endpoints. Cumulative incidence 
of healing at 12, 20 and 52 weeks post randomisation will be obtained from the primary endpoint 
analysis model.  A Poisson-Gamma regression model will be fitted to infection status over time. A Cox 
Proportional Hazard’s regression model will be fitted to time to re-ulceration of the index ulcer on 
those patients where healing of the index ulcer is confirmed. A repeated measures, random 
coefficients, linear regression model will be fitted to the DFS-SF score over time. 
All adverse events and serious adverse events, including amputations and admissions to hospital, will 
be recorded and summarised by treatment strategy received. Expected treatment-related adverse 
events (AEs) include: pain, bleeding and infection from hydrosurgical debridement; bleeding, infection 
and skin irritation/breakdown from NPWT; seroma and allergic reaction from DCD.
Exploratory Analyses
Sensitivity analyses
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For all analyses using the Cox Proportional Hazard’s model, the assumption of independence of the 
distribution of time to healing /recurrence and time to other events, i.e. amputation and death will be 
assessed and alternative models considered if there are sufficient competing risks.
A multivariable Cox Proportional Hazards regression model will be fitted to explore risk factors 
predictive of time to healing. 
Economic evaluation
A within-trial economic evaluation will be undertaken at week 52 post-randomisation. The proposed 
secondary endpoints and methods for the economic evaluation follow the reference case set out by 
NICE (34). The primary economic analysis will be a cost-utility analysis presenting incremental cost-
effectiveness ratios (ICER) for each treatment strategy in rank order of effectiveness, with effects 
expressed in terms of quality-adjusted life years (QALY).  An NHS and Personal Social Services 
(PSS) perspective for costs will be adopted.  Costs and effects for each treatment strategy will be 
calculated for the trial follow-up period of 52 weeks.
Health resource use questionnaires will collect information on NHS and personal social care use in 
line with NICE guidelines (34). This will include primary, secondary, and community resource use. 
Unit cost data will be obtained from national databases such as the British National Formulary and 
Personal Social Services Research Unit (PSSRU) Costs of Health and Social Care.
Treatment costs include the cost of delivering each strategy (mainly given by person-time of health-
care professionals) and the cost of the necessary equipment. The scope of resources considered 
includes the direct healthcare costs incurred for necessary patient care and excludes resources 
driven by the study protocol (e.g., routine clinics will be included, whilst research visits that are just for 
checking for re-ulceration are excluded; also, the cost of photography and visit time for collecting data 
for study purposes will be excluded). To cost the treatment strategies, data on average duration of 
appointments for delivering the treatment strategy will be collected.
 
Incremental cost-effectiveness ratios, Incremental Net Monetary Benefit (INMB) and Incremental Net 
Health Benefit (INHB) statistics will be computed.  The National Institute for Health and Care 
Excellence (NICE) considers a cost per QALY within the range of £20,000-£30,000 to be acceptable 
(34). 
Multiple Imputation will be used to address any issues of missing data in the base case analysis on 
the assumption of MAR.  Complete Case analysis will be conducted as a sensitivity analysis.
 
Probabilistic Sensitivity Analysis (PSA) will be used to assess the impact of sampling uncertainty on 
the within trial evaluation results.  Simulated cost and QALY estimates will be plotted on the cost-
effectiveness plane to illustrate the uncertainty surrounding cost-effectiveness estimates (35) and 
presented  as cost-effectiveness acceptability frontier (CEAF) to capture the varying probability of 
interventions being the most cost-effective over a range of willingness to pay for a QALY thresholds 
(36)
In addition, alternative scenarios will be explored in the sensitivity analysis to test the robustness of 
the main trial analysis results including analysis of complete cases only.
Data Management
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Data will be monitored for quality and completeness and missing data will be chased up. Data 
received, including photographs will be stored in a secure database at Leeds CTRU in accordance 
with the 2018 Data Protection Act and the General Data Protection Regulation (GDPR). 
Patient and Public Involvement
The trial was supported at the stage of developing the grant application by the Sheffield Teaching 
Hospitals Lay Advisory Panel for Diabetes & Endocrinology Research. Their input was central to 
study design, actively helping to shape discussions and decisions through written feedback and group 
discussion. In particular they informed decisions on the how frequently patients should be reassessed 
at the study site; whether patients would be willing to report healing or other outcomes directly to the 
research team or through their community clinician; agreement to completion of questionnaires, 
wound tracing and photographs which may be considered a burden; how willing patients will be to 
take part in the study; the acceptability of each intervention.
The trial has two PPI representatives on the Trial Steering Committee who have provided input into 
the patient information sheet and other trial documentation intended for use by patients.  The PPI 
representatives also provide input into the design and conduct of the trial at 6 monthly meetings. This 
high-level involvement in project management aims to ensure patients perspectives are fully 
integrated in key decisions about the trial, delivery, and interpretation/dissemination of findings.
Ethics and Dissemination: Informed consent was provided by participants prior to commencement 
of their study.  Ethics approval has been granted by NRES Committee Yorkshire & The Humber - 
Bradford Leeds Research Ethics Committee; approved 26th April 2017; (REC reference: 17/YH/0055). 
There is planned publication of a monograph in NIHR journals and main trial results and associated 
papers in high-impact peer reviewed journals.
Discussion
MAMS design:
The chosen MAMS design provides an efficient platform for assessment of several competing 
interventions, quickly homing in on the treatment strategy with greatest potential to be effective, early 
dropping of ineffective treatments and allowing assessment of combinations of treatments (20, 37-39). 
Specific advantages of the MAMS design include comparing multiple treatment arms to a shared 
control group thereby requiring fewer patients, improved consent/ recruitment rates since patients are 
more likely to receive an active treatment (39) and common eligibility criteria across trial arms (20). 
Moreover, recruitment to all treatment strategies will continue during analysis and reporting of Phase 
II data to ensure no loss of momentum in recruitment at sites. 
Choice of endpoints:
Reduction in ulcer area at 4 weeks was chosen as the primary outcome at Phase II to be consistent 
with published observational studies (40, 41) and DFU RCTs (42). This intermediate outcome 
measure provides a means of screening for “emerging evidence” of efficacy, as it occurs earlier and 
more frequently than the definitive outcome measure and that it is on the causal pathway (43). Thus, 
it allows the Phase II analysis and decision on treatment selection to take place in a timely manner.
Time to healing, the primary endpoint in Phase III, was chosen as an important outcome measure 
from both clinical and economic perspectives (32).
Ulcer infection is the most common complication in non-healing ulcers, occurring in more than 50% of 
DFUs (6). It results in delayed healing, prolonged treatment, increased resource use and increases 
the risk of a patient requiring a major amputation (44). IDSA criteria is recognised as a gold standard 
for characterisation of infection in DFUs in many national and international guidelines and will provide 
a reproducible system for clinical diagnosis and severity stratification (12) (21) (45).
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No single patient-reported outcome measure (PROM) has been identified as a “gold standard” for 
assessing HRQOL in diabetes-related foot disease (46). As a result, both the disease-specific 
questionnaire, DFS-SF (47) and the preference-based utility measure, EQ-5D-5L (www.euroqol.org)  
(48), will be completed by patients. The DFS-SF questionnaire has acceptable psychometric 
properties for measuring quality of life for patients with DFUs. The EQ-5D is a generic instrument and 
forms part of the NICE reference case for cost per Quality Adjusted Life Years (QALY) analysis. 
Blinded assessment of healing
Having a blinded assessment of healing is important in reducing the risk of assessment bias and the 
trial includes independent, blinded clinical assessment of healing at both the first and confirmation of 
healing assessments, along with additional blinded review of photography undertaken by clinicians 
(CI (vascular surgeon) and clinical nurse specialists).
Revision to trial design
Since opening, the trial has undergone a trial re-design. The original design included a fourth 
treatment strategy in Phase II corresponding to a combination of HD and NPWT as an adjunct to 
TAU, and also allowed a maximum of two treatment strategies to go forward into Phase III under the 
same progression criteria. This original design required a maximum sample size of 660 participants, 
324 participants recruited in Phase II and 336 in Phase III, under the sample size assumptions.   
Following a review of treatment strategies which would be considered in clinical practice if shown to 
be clinically and cost effective, a revised trial design dropped the combination of HD and NPWT arm, 
which reduced the maximum sample size to 447 patients whilst still ensuring a trial of clinical 
relevance.
Hard-to-heal ulcers
A registration phase was also included in the original trial design. It is important that the trial includes 
a patient population with “hard-to-heal” ulcers, reflecting the target population that would be 
considered for such adjuvant therapies in clinical practice. As there is variability in usual wound area 
assessment and documentation across recruiting centres, the registration phase included in the 
original design allowed a consistent approach to assessment of healing over a 4-week run-in period, 
and thereby considered “best practice” for trials of DFU healing. However, the recently published 
LeucoPatch trial (49), using an identical registration phase criterion of 50% healing at 4 weeks, 
reported only 22% healing in the control and 34% healing in the intervention arm, suggesting that this 
registration phase criteria is overly selective in the definition of “hard-to-heal”. Early audit of data from 
a single centre in MIDFUT showed that patients were not recruited to the trial at presentation to an 
MDT DFU clinic, and had been subjected to an “in house assessment period” prior to registration in 
the trial. 75% of those failing the trial registration period due to ulcer healing of >50% remained 
unhealed at 12 weeks, suggesting the trial was excluding a group of ulcers that were in fact “hard-to-
heal”. The 2018 UK National Diabetic Foot Care Audit data of 21,000 ulcer episodes reports 49.3% 
remain unhealed at 12 weeks, with 27.3% unhealed 24 weeks and a further 2.9% recurring. Thus 
under half of ulcers unhealed at 12 weeks will heal in the subsequent 12 weeks, supporting a second 
inclusion criterion of ulcers that remain unhealed at a 12-week timepoint (9). A parallel entry route 
was therefore introduced to allow patients with ulcers of 12 weeks duration, that are considered 
hard-to-heal by the treating MDT team, to proceed directly to randomisation.
Following challenges in recruiting patients and the supporting evidence that a large proportion of 
patients with hard-to-heal ulcers were being missed, a decision was made to drop the Registration 
phase for all patients.  Instead, included ulcers will have failed to reduce in area by >50% over at least 
4 weeks as measured using local measurement techniques. This allows a more pragmatic approach 
to be taken in identifying patients with hard to heal ulcers by using local wound measurement policies, 
thereby minimises the risk of missing potentially eligible patients whilst ensuring the trial results are 
more generalisable to the target patient population.
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Adjuvant therapies
It is not anticipated that there will be a rapid change in the technologies investigated in this trial, other 
than design changes aimed at increasing clinician and patient acceptance, again increasing the 
potential adoption and generalisability of the trial outcomes.
Trial Status
The first participant was registered on 10th August 2017 and the first participant randomised on 30th 
October 2017.  As of 4th December 2019, 167 participants have been registered and 88 randomised.  
Recruitment is expected to complete by 31st August 2022. The full trial protocol is available on the 
NIHR journals library https://www.journalslibrary.nihr.ac.uk/programmes/hta/150877/#/. 
Declarations 
Data Availability
The datasets during and/or analysed during the current study will be available from the corresponding 
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PIL Participant Information Leaflet
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QALY Quality Adjusted Life Years
RCT Randomised Controlled Trial
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RUSAE Related Unexpected Serious Adverse Event
SAE Serious Adverse Event
SWAT Study Within a Trial
TAU Treatment as Usual
TS Treatment Strategy
TSC Trial Steering Committee
WHO World Health Organisation
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Figure Legends:
Figure 1: MIDFUT trial design 
Figure 2: Flow Diagram
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Figure 1: MIDFUT trial design
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Figure 2: Flow Diagram 
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and 
related documents*
Section/item Item
No
Description
Administrative information
Title 1 Descriptive title identifying the study design, population, 
interventions, and, if applicable, trial acronym
Page 1
2a Trial identifier and registry name. If not yet registered, name of 
intended registry
Page 2Trial registration
2b All items from the World Health Organization Trial Registration 
Data Set
N/A
Protocol version 3 Date and version identifier Page 16
Funding 4 Sources and types of financial, material, and other support Page 17
5a Names, affiliations, and roles of protocol contributors Pages 1, 
17
Roles and 
responsibilities
5b Name and contact information for the trial sponsor Page 16
(see link to 
Protocol)
5c Role of study sponsor and funders, if any, in study design; 
collection, management, analysis, and interpretation of data; writing 
of the report; and the decision to submit the report for publication, 
including whether they will have ultimate authority over any of these 
activities
Page 17
5d Composition, roles, and responsibilities of the coordinating centre, 
steering committee, endpoint adjudication committee, data 
management team, and other individuals or groups overseeing the 
trial, if applicable (see Item 21a for data monitoring committee)
Page 17
Introduction
Background and 
rationale
6a Description of research question and justification for undertaking 
the trial, including summary of relevant studies (published and 
unpublished) examining benefits and harms for each intervention
Pages 
3 & 4
6b Explanation for choice of comparators Pages 
3 &4
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Objectives 7 Specific objectives or hypotheses Pages 
4 & 5
Trial design 8 Description of trial design including type of trial (eg, parallel group, 
crossover, factorial, single group), allocation ratio, and framework 
(eg, superiority, equivalence, noninferiority, exploratory)
Pages 
5 & 7 
Methods: Participants, interventions, and outcomes
Study setting 9 Description of study settings (eg, community clinic, academic 
hospital) and list of countries where data will be collected. 
Reference to where list of study sites can be obtained
Page 
6
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, 
eligibility criteria for study centres and individuals who will perform 
the interventions (eg, surgeons, psychotherapists)
Pages 
6-8
11a Interventions for each group with sufficient detail to allow 
replication, including how and when they will be administered
Pages
8&9
11b Criteria for discontinuing or modifying allocated interventions for a 
given trial participant (eg, drug dose change in response to harms, 
participant equest, or improving/worsening disease)
N/A
11c Strategies to improve adherence to intervention protocols, and any 
procedures for monitoring adherence (eg, drug tablet return, 
laboratory tests)
N/A
Interventions
11d Relevant concomitant care and interventions that are permitted or 
prohibited during the trial
N/A
Outcomes 12 Primary, secondary, and other outcomes, including the specific 
measurement variable (eg, systolic blood pressure), analysis metric 
(eg, change from baseline, final value, time to event), method of 
aggregation (eg, median, proportio ), and time point for each 
outcome. Explanation of the clinical relevance of chosen efficacy 
and harm outcomes is strongly recommended
Pages
4, 5 & 8
Participant 
timeline
13 Time schedule of enrolment, interventions (including any run-ins 
and washouts), assessments, and visits for participants. A 
schematic diagram is highly recommended (see Figure)
Pages 
8-10
Sample size 14 Estimated number of participants needed to achieve study 
objectives and how it was determined, including clinical and 
statistical assumptions supporting any sample size calculations
Page
10
Recruitment 15 Strategies for achieving adequate participant enrolment to reach 
target sample size
Pages 
6 & 7
Methods: Assignment of interventions (for controlled trials)
Allocation:
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Sequence 
generation
16a Method of generating the allocation sequence (eg, computer-
generated random numbers), and list of any factors for 
stratification. To reduce predictability of a random sequence, details 
of any planned restriction (eg, blocking) should be provided in a 
separate document that is unavailable to those who enrol 
participants or assign interventions
Page 7
Allocation 
concealment 
mechanism
16b Mechanism of implementing the allocation sequence (eg, central 
telephone; sequentially numbered, opaque, sealed envelopes), 
describing any steps to conceal the sequence until interventions 
are assigned
Page 7
Implementation 16c Who will generate the allocation sequence, who will enrol 
participants, and who will assign participants to interventions
Page 7
Blinding 
(masking)
17a Who will be blinded after assignment to interventions (eg, trial 
participants, care providers, outcome assessors, data analysts), 
and how
Page 8
17b If blinded, circumstances under which unblinding is permissible, 
and procedure for revealing a participant’s allocated intervention 
during the trial
N/A
Methods: Data collection, management, and analysis
Data collection 
methods
18a Plans for assessment and collection of outcome, baseline, and 
other trial data, including any related processes to promote data 
quality (eg, duplicate measurements, training of assessors) and a 
description of study instruments (eg, questionnaires, laboratory 
tests) along with their reliability and validity, if known. Reference to 
where data collection forms can be found, if not in the protocol
Pages
9, 10 & 14
18b Plans to promote participant retention and complete follow-up, 
including list of any outcome data to be collected for participants 
who discontinue or deviate from intervention protocols
N/A
Data 
management
19 Plans for data entry, coding, security, and storage, including any 
related processes to promote data quality (eg, double data entry; 
range checks for data values). Reference to where details of data 
management procedures can be found, if not in the protocol
Page 14
Statistical 
methods
20a Statistical methods for analysing primary and secondary outcomes. 
Reference to where other details of the statistical analysis plan can 
be found, if not in the protocol
Pages 
12 & 13
20b Methods for any additional analyses (eg, subgroup and adjusted 
analyses)
Page 13
20c Definition of analysis population relating to protocol non-adherence 
(eg, as randomised analysis), and any statistical methods to handle 
missing data (eg, multiple imputation)
Page 12
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Methods: Monitoring
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its 
role and reporting structure; statement of whether it is independent 
from the sponsor and competing interests; and reference to where 
further details about its charter can be found, if not in the protocol. 
Alternatively, an explanation of why a DMC is not needed
Page 11
21b Description of any interim analyses and stopping guidelines, 
including who will have access to these interim results and make 
the final decision to terminate the trial
Page 11
Harms 22 Plans for collecting, assessing, reporting, and managing solicited 
and spontaneously reported adverse events and other unintended 
effects of trial interventions or trial conduct
Page 12
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and 
whether the process will be independent from investigators and the 
sponsor
N/A
Ethics and dissemination
Research ethics 
approval
24 Plans for seeking research ethics committee/institutional review 
board (REC/IRB) approval
Pages 
2 & 14
Protocol 
amendments
25 Plans for communicating important protocol modifications (eg, 
changes to eligibility criteria, outcomes, analyses) to relevant 
parties (eg, investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators)
N/A
Consent or assent 26a Who will obtain informed consent or assent from potential trial 
participants or authorised surrogates, and how (see Item 32)
Pages
6 & 7
26b Additional consent provisions for collection and use of participant 
data and biological specimens in ancillary studies, if applicable
N/A
Confidentiality 27 How personal information about potential and enrolled participants 
will be collected, shared, and maintained in order to protect 
confidentiality before, during, and after the trial
Page 14
Declaration of 
interests
28 Financial and other competing interests for principal investigators 
for the overall trial and each study site
Page 17
Access to data 29 Statement of who will have access to the final trial dataset, and 
disclosure of contractual agreements that limit such access for 
investigators
Page 16
Ancillary and 
post-trial care
30 Provisions, if any, for ancillary and post-trial care, and for 
compensation to those who suffer harm from trial participation
N/A
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Dissemination 
policy
31a Plans for investigators and sponsor to communicate trial results to 
participants, healthcare professionals, the public, and other 
relevant groups (eg, via publication, reporting in results databases, 
or other data sharing arrangements), including any publication 
restrictions
Page 14
31b Authorship eligibility guidelines and any intended use of 
professional writers
N/A
31c Plans, if any, for granting public access to the full protocol, 
participant-level dataset, and statistical code
Page 16
Appendices
Informed consent 
materials
32 Model consent form and other related documentation given to 
participants and authorised surrogates
N/A
Biological 
specimens
33 Plans for collection, laboratory evaluation, and storage of biological 
specimens for genetic or molecular analysis in the current trial and 
for future use in ancillary studies, if applicable
N/A
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 
Explanation & Elaboration for important clarification on the items. Amendments to the 
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT 
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” 
license.
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